Figure 2.

Tumor growth suppressive effect of DFP‐10825 in a MKN45 peritoneally disseminated mouse model. Luciferase‐expressing MKN45 peritoneally disseminated model mice were injected with either DFP‐10825 (20 µg/mouse/d, four doses once every 3 d, i.p.) or S‐1 (3.5 mg tegafur/kg/d, 14 doses once every day, p.o.) from Day 7 post‐tumor implantation. A, Bioluminescence of the disseminated tumors was monitored with in vivo imaging system at selected time points (Days 7, 14, 18, and 21 post‐tumor implantation). Two of 10 mice in the DFP‐10825‐treated group died accidently due to excessive anesthesia. B, Bioluminescent intensities of the disseminated tumors were calculated from the images in Figure 2A. The data are represented as the mean ± SD (n = 10, *P < .05, **P < .01 vs control, ^# P < .05 vs S‐1). C, Body weight changes of the mice were monitored at selected time points. The data are represented as the mean ± SD